By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panel is divided on Maravai's Q1 performance and future outlook. While some see a turnaround with strong growth and improved margins, others question the sustainability of the growth and the reliance on large orders and new product adoption.
Risk: Reliance on large orders and the timing/scale of new product adoption (Motto) could lead to volatility and potential EBITDA misses.
Opportunity: Sustained high-margin growth from TriLink and successful adoption of new products like the GMP enzyme and Motto could drive further EBITDA expansion.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Image source: The Motley Fool.
May 7, 2026
- Chief Executive Officer — Bernd Brust
- Chief Financial Officer — Rajesh Asarpota
- Chief Scientific Officer — Chanfeng Zhao
- Investor Relations — Debra Hart
Need a quote from a Motley Fool analyst? Email [email protected]
Debra Hart: Good afternoon, everyone. Thanks for joining us for our first quarter 2026 earnings call. The press release and slides accompanying today's call are posted on our website and available at investors.maravai.com. As you can see from the agenda on Slide 2, our CEO, Bernd Brust, will provide a business update and our CFO, Rajesh Asarpota, will review our financial results. Chanfeng Zhao, our Chief Scientific Officer, will join us for the Q&A session. Management will make forward-looking statements and refer to GAAP and non-GAAP financial measures during today's call. It is possible that actual results could differ from expectations. We refer you to Slide 3 for details on forward-looking statements and our use of non-GAAP financial measures.
The press release provides reconciliations to the most directly comparable GAAP measures and we also post reconciling schedules to our investor website. Please also refer to Maravai LifeSciences Holdings, Inc.’s SEC filings for additional information on the risks and uncertainties that may impact our operating results, performance, and financial condition. Now I will turn the call over to Bernd. Good afternoon, and thank you for joining us.
Bernd Brust: We are very pleased with our first quarter performance, which represents a strong start to 2026 and builds on the momentum we exited with last year. The quarter results reflect solid execution across the business and reinforce our confidence in the trajectory we outlined on our call in February. Turning to Slide 5, we delivered total Q1 revenue of $65.8 million. That is 41% year-over-year growth, and 10% year-over-year growth in our base business when you exclude COVID-related CleanCap revenue. This performance was driven by improved TriLink demand, steady contribution from Cygnus, and continued progress against our strategic priorities.
TriLink revenue grew 65% year over year, with base business growth of 15%, supported by strong demand in both GMP and discovery consumables. At Cygnus, revenue grew a little more than 1% year over year. We saw solid underlying momentum with high single-digit growth in North America and low single-digit growth in EMEA, reinforcing our confidence in the positioning of the business. This was partially offset by lower contribution from China due to distributor ordering timing. From a profitability standpoint, we delivered adjusted gross margin of 65.3% and adjusted EBITDA of $20.3 million. These results reflect the benefit of higher revenue, favorable product and customer mix, and the cost disciplines we have implemented across the organization.
We also generated $4.2 million of positive free cash flow in the quarter, which is the first time the company has been cash flow positive since 2024. We see this as another clear indication that the structural improvements we have made are taking hold. Given our strong start to the year and improved visibility into the balance of 2026, we are increasing the range for our full-year revenue expectations and substantially raising our EBITDA guidance. Raj will walk through that in more detail shortly. Now let us turn to Slide 6 for an update on our performance against our three strategic pillars: commercial execution, operational excellence, and, of course, innovation.
Starting with commercial execution, we are seeing strong momentum across the business. Our increased focus on customer engagement is translating into better forecasting, improved visibility, and stronger order conversion. We are securing more annual and multi-quarter purchase orders, which is improving the stability and predictability of our revenue base. This is a meaningful shift from where we were a year ago and reflects the effectiveness of the changes we have made in our commercial go-to-market approach. That said, our business has a disproportionate number of large orders that can result in quarter-over-quarter performance variation. Large orders tend to align with customer program progression, and as a result, revenue can vary between periods.
What gives us confidence is not the timing of any single order, but the strength and continued expansion of the underlying opportunity funnel. Within TriLink, our portfolio now spans enabling technologies such as CleanCap and Motto, along with custom and catalog mRNA enzymes, oligonucleotides including guide RNAs, and a broad range of nucleotide chemistries, including NTPs. This breadth allows us to participate more deeply across the mRNA and gene therapy workflows. We also recently launched all-in-one IVT kits, which simplify the production of capped RNA and provide early-stage researchers with easier access to our platform. At TriLink, our model continues to work as intended.
We establish relationships early in discovery, embed our technologies in customer workflows, and then grow with those programs as they advance into GMP. Mentions of TriLink technologies in scientific publications remain strong, underscoring their role in customer workflows, which we view as an important leading indicator of future demand. A key highlight in the quarter is the continued adoption of Motto. We now have more than 70 customers using this technology across both large pharmaceutical companies and emerging biotechs. We are seeing growth in new customers, repeat orders, and increasing use across multiple applications.
We also see continued strength in our GMP funnel, with GMP customers expected to grow 22% in 2026, representing nine existing RUO customers transitioning to GMP customers, two of which we have already converted this year. Many of these programs are progressing into later clinical stages, which supports the durability of the demand as a long-term GMP supplier. At Cygnus, we saw growth from our newer DNA quantification and extraction kits, as well as from our MockV product offering. These product lines extend us beyond our traditional HCP franchise into adjacent applications. While still early, we are encouraged by the traction we are seeing as customers look for high-quality analytical tools across their development and manufacturing workflows.
And finally, at Cygnus, our kits continue to play a critical role in the market with a 100% attach rate supporting the safety testing of all 29 of the 29 FDA- or EMA-approved CAR T cell and gene therapies. Now turning to operational excellence. This remains a core focus and a key driver of our improved financial performance. The restructuring actions we implemented last year continue to deliver results, and we now expect to achieve more than $65 million in annual EBITDA savings. These savings span labor, facilities, and controllable spend and are creating a more efficient and scalable cost structure. This is clearly reflected in our margins.
We are benefiting from both cost discipline and a favorable product mix, particularly as higher-margin GMP consumables represent a larger portion of our revenue. At the same time, our operating model is now positioned to absorb incremental volume without significant increases in fixed costs, supporting continued margin expansion as we grow revenue. We are also making progress on our digital and operational initiatives. Our e-commerce channel continues to expand, with more customers placing orders directly through our platform, improving speed and efficiency. In Q1, our website delivered record revenue, reflecting both improved customer engagement and the scalability of our digital platform. Finally, turning to R&D.
Our focus remains on translating innovation into revenue and strengthening our competitive position across our customers' workflows. At TriLink, we are making strong progress on our enzymes portfolio. Our GMP facility has now been completed, and we expect to launch GMP-quality enzymes this quarter. Early customer engagement has been encouraging, and we see this as an important extension of our capabilities. With Motto, we are building on the strong discovery adoption and expect to launch GMP-grade Motto later this year. We are already seeing customer demand for GMP material to support clinical programs. This is a clear example of how our innovation pipeline feeds future revenue growth.
More broadly, our portfolio continues to diversify across custom mRNA, kits, and catalog mRNA, complementing our existing CleanCap and oligo product lines. This strengthens our position and reduces reliance on any single product or customer. At Cygnus, in addition to host cell protein assays, which remain the gold standard for clinical and commercial drug product lot release, we now offer an expanded suite of HCP analytical services utilizing advanced mass spectrometry methods and state-of-the-art instruments. These innovative analytical capabilities deliver critical insights to customers throughout drug development and into commercialization, helping ensure their products remain safe and effective. We continue to invest in and expand our IP portfolio across our core platforms, including CleanCap, Motto, and Cygnus assays.
During the first quarter, TriLink received two additional European patents, including one further strengthening protection around our CleanCap technology and methods for synthesizing RNA. In addition, Cygnus was granted a new U.S. patent related to its MVP mock viral particle technology, supporting our assay and analytical capabilities. In summary, the first quarter represents an incredible start to the year. We are executing well across all three pillars: driving commercial momentum, delivering operational discipline, and advancing innovation. The fundamentals of the business are strong, and we believe we are well positioned for continued growth, margin expansion, and cash generation in 2026 and beyond. I will now ask Rajesh to provide details on our first quarter performance and our updated guidance. Rajesh?
Rajesh Asarpota: Thank you, Bernd. Building on Bernd's comments, the first quarter reflects solid execution across both segments with improving base demand and strong margin flow-through. I will focus on the key drivers behind the quarter, including revenue composition, profitability, and our updated outlook. Let me start with a closer look at revenue on Slide 8. Our business remains well diversified across end markets. Base revenue by customer type was 32% biopharma, 31% life sciences and diagnostics, 4% academia, 7% CRO/CMO/CDMO, and 26% distributors. By geography, base revenue was 60% North America, 25% EMEA, 8% Asia Pacific excluding China, and 7% in China. Turning to Slide 9, our GAAP net loss before non-controlling interest was $6.4 million.
This compares to a GAAP net loss before non-controlling interest of $52.9 million in the prior-year period. Adjusted EBITDA, a non-GAAP measure, was $20.3 million for Q1, exceeding our expectations and improving by more than $30 million year over year. This was driven by stronger revenue, favorable mix toward high-margin GMP and discovery consumables, and high-margin contribution from COVID CleanCap. Basic and diluted loss per share in Q1 was $0.02 compared to a loss of $0.21 per share in Q1 2025. Adjusted EPS was positive $0.01 compared to a loss of $0.08 per share last year.
Moving to the balance sheet, cash flow, and other financial metrics on Slide 10, we ended the quarter with $165.9 million in cash, and $242.9 million in long-term debt following the voluntary $50 million debt repayment during the quarter. We generated $4.2 million of positive free cash flow reflecting improved EBITDA and disciplined capital management. Depreciation and amortization was $11.4 million, net interest expense was $3.9 million, and stock-based compensation, a noncash charge, was $6.7 million for the quarter. Turning to segment performance on Slide 11, TriLink represented 72% of total revenue in the quarter. Excluding COVID CleanCap, TriLink represented 64% of total revenue with base growth of 15%.
TriLink was a primary driver of adjusted EBITDA improvement, benefiting from high-margin product mix and improved operating leverage. The segment generated $17.3 million of adjusted EBITDA, representing an improvement of more than $26 million year over year. Cygnus represented 28% of total revenue, or 36% of base revenue, and continued to deliver strong profitability. Cygnus generated $13.6 million of adjusted EBITDA with margins of 73.8%. Corporate expenses impacting adjusted EBITDA were $10.5 million in the quarter. These expenses include HR, finance, legal, IT, and public company costs. Turning to our updated guidance on Slide 12, our outlook reflects a strong first quarter and increased confidence in the base business trajectory.
We are raising our revenue range to $205 million to $215 million, representing growth of 10% to 16% over 2025. We expect TriLink to grow in the high teens driven by continued strength in GMP consumables and a return to growth in discovery. We do not currently expect additional high-volume COVID CleanCap revenue in 2026; however, we continue to view $10 million to $20 million of annual endemic demand as a reasonable baseline longer term. For Cygnus, we continue to expect low- to mid-single-digit growth, and we view the Q1 softness in China as timing-related.
We are substantially raising our full-year adjusted EBITDA guidance to $30 million to $32 million, representing an improvement of $61 million to $63 million year over year, supported by restructuring actions, cost discipline, and favorable product mix. The remainder of our guidance framework we provided on the February call is unchanged. Importantly, we expect to generate positive free cash flow for the remainder of the year, representing a meaningful improvement from 2025. Overall, we are encouraged by the momentum in the business. Improved commercial execution, a more efficient cost structure, and favorable mix are driving meaningful financial progress, and we remain confident in our outlook for 2026.
With that, I will turn the call back over to the operator for Q&A.
Operator: Thank you. We will now open the call for questions. To leave the queue at any time, please press 2. Once again, that is 1 to ask a question. Please limit yourself to one question and one follow-up. We will pause for just a moment to allow everyone a chance to join the queue. Thank you. We will take our first question from Matthew Gregory Hewitt with Craig-Hallum Capital Group. Please go ahead. Your line is open.
Matthew Gregory Hewitt: Well, congratulations on a very nice start to the year. Maybe first up, and real high level, I am just curious what you are seeing from your pharma customers both seg
Four leading AI models discuss this article
"Maravai has successfully transitioned from a COVID-dependent entity to a structurally leaner supplier with sustainable operating leverage in the gene therapy workflow."
Maravai’s Q1 print is a classic 'turnaround story' validation. The return to positive free cash flow, coupled with a massive $60M+ EBITDA guidance hike, suggests the restructuring is finally yielding operating leverage. The 15% base growth at TriLink is the real engine here, signaling that the biopharma R&D environment is thawing. However, the reliance on 'large order' timing remains a volatility risk. While the 100% attach rate at Cygnus provides a defensive moat, the company is still essentially a high-beta play on the mRNA and gene therapy pipeline. I am cautiously optimistic that the worst of the post-COVID hangover is behind them.
The guidance raise is heavily predicated on 'timing' and cost-cutting rather than organic volume acceleration, and any slowdown in clinical program progression would immediately expose the fragility of their concentrated customer base.
"MRVI's $65M+ cost savings and 22% GMP customer expansion enable 15%+ base growth and EBITDA margins north of 50% through 2027."
MRVI delivered a stellar Q1 2026 with $65.8M revenue (+41% YoY, +10% base ex-COVID CleanCap), $20.3M adj EBITDA (gross margin 65.3%), and $4.2M positive FCF—first since 2024—fueled by TriLink's +15% base growth (GMP funnel +22% customers), Cygnus steadiness, and >$65M annual restructuring savings. Raised FY guidance to $205-215M revenue (+10-16% YoY) and $30-32M EBITDA (+$61-63M YoY), with high-teens TriLink growth and GMP launches (enzymes Q2, Motto later). This validates post-COVID recovery in mRNA/gene therapy consumables, with e-commerce and mix driving leverage.
Revenue remains lumpy due to large orders tied to customer timelines, risking Q2-Q4 misses despite raised guidance; China distributor timing at Cygnus could signal deeper demand weakness amid regulatory headwinds.
"MRVI has fixed its cost structure and achieved positive FCF, but revenue growth deceleration and reliance on large lumpy GMP orders create visibility risk that the 10-16% full-year guide may prove optimistic if Q2 order timing slips."
MRVI's Q1 shows genuine operational inflection: 41% YoY revenue growth, first positive FCF since 2024, adjusted EBITDA of $20.3M (vs. $-10M prior year), and 65.3% gross margins. The $65M restructuring savings are materializing. However, the guidance raise to $205-215M (10-16% growth) is modest relative to Q1's 41% print, and management explicitly warns of 'disproportionate large orders' causing volatility. The TriLink base business grew only 15% ex-COVID; that's deceleration from prior quarters. Cygnus grew just 1% YoY. COVID CleanCap is being written down to $10-20M endemic demand, a material headwind.
The 'strong start' narrative masks that core TriLink discovery is slowing (15% base growth), China distributor timing is a red flag for Asia exposure, and the company is still guiding to single-digit Cygnus growth despite claiming operational excellence.
"MRVI is on a path to structurally higher margins and cash flow in 2026 due to a diversified, high‑margin TriLink/Cygnus mix and cost discipline, with risk primarily in order cadence and China timing rather than a collapse in demand."
Maravai posted a strong Q1 2026 with $65.8m revenue, up 41% y/y, and adjusted EBITDA of $20.3m, while free cash flow turned positive for the first time since 2024. The driver mix tilts toward high-margin GMP/Discovery through TriLink and Cygnus, supporting an expanded EBITDA guide of $30–$32m and a raised revenue range of $205–$215m for 2026. The narrative hinges on a durable commercial engine, improving visibility from longer-term purchase orders, and a healthy product mix, aided by the new GMP enzyme launch and Motto adoption. However, sensitivity to large one-off orders, China timing, and the still-elevated leverage shadow the upside.
The strongest counter is that the quarter’s strength may be temporarily inflated by endemic COVID‑related CleanCap revenue and a few large orders that won’t repeat; if TriLink’s growth slows, China remains a timing risk, and the debt burden limits optionality, the raised guidance could prove too optimistic.
"The valuation hinges entirely on the Motto platform's ability to replace declining COVID-era revenue streams, making the current EBITDA guidance highly sensitive to adoption rates."
Claude, your focus on the 15% TriLink base growth as a 'deceleration' misses the critical inflection point: the shift from volume-heavy COVID dependency to higher-margin, non-COVID GMP revenue. While you fear the China distributor timing, the real risk is the 'Motto' platform adoption curve. If Motto doesn't scale rapidly in H2 2026 to offset the CleanCap write-downs, the EBITDA guidance isn't just optimistic—it's mathematically unreachable. We are betting on a product transition, not just a recovery.
"FY guidance reveals Q1 strength was lumpy order timing, with QoQ revenue implied to drop 25-30%, exposing H2 fragility."
Gemini, your Motto pivot dodges Claude's core math: Q1's $65.8M revenue (41% YoY) vs FY guide $205-215M implies Q2-Q4 average ~$47-50M (down 25-30% QoQ). That's not GMP inflection—it's large-order front-loading. Restructuring savings mask it, but any GMP enzyme delay (Q2 launch) craters H2 EBITDA. Volatility isn't thawing; it's baked in.
"Front-loading risk is real, but management's EBITDA raise despite known lumpy revenue suggests they have visibility into H2 product launches—or they're lying."
Grok's math is airtight—Q1's $65.8M annualizes to ~$263M, but FY guide tops $215M. That's not conservatism; it's front-loading. But neither Grok nor Gemini address the elephant: if large orders ARE pulling forward, management knows it. Why raise EBITDA guidance $61-63M if they expect Q2-Q4 to crater? Either they're confident in Motto/enzyme ramps, or the guidance is fiction. That's the real test.
"The real risk is that Motto/GMP ramp timing and China headwinds could wipe out the EBITDA upside, making the FY205-215m guide contingent on front-loaded orders that may not repeat."
Grok's front-loading worry is valid but incomplete: a Q2-Q4 glide path of $47-50m would imply near-term pressure, yet the company could still hit $30-32m EBITDA if Motto enacts a rapid scale and TriLink sustains 15%+ base growth. The bigger risk is reliance on a few large orders and the timing/scale of Motto; even with $65m restructuring savings, any delay in Motto/GMP ramp or China headwinds could erode H2 EBITDA more than assumed.
The panel is divided on Maravai's Q1 performance and future outlook. While some see a turnaround with strong growth and improved margins, others question the sustainability of the growth and the reliance on large orders and new product adoption.
Sustained high-margin growth from TriLink and successful adoption of new products like the GMP enzyme and Motto could drive further EBITDA expansion.
Reliance on large orders and the timing/scale of new product adoption (Motto) could lead to volatility and potential EBITDA misses.